Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer
Myrto Moutafi(University General Hospital Attikon), Amanda Psyrri(National and Kapodistrian University of Athens), Ioannis G. Panayiotides(National and Kapodistrian University of Athens), Christos Poulios(Aristotle University of Thessaloniki), Niki Gavrielatou(National and Kapodistrian University of Athens), Thazin Nwe Aung(Yale University), Dimitrios Pectasides(National and Kapodistrian University of Athens), Periklis Foukas(National and Kapodistrian University of Athens), Evangelos Giotakis(National and Kapodistrian University of Athens), David L. Rimm(Yale University), Georgia-Angeliki Koliou(Hellenic Cooperative Oncology Group), Andromachi Kougioumtzopoulou(National and Kapodistrian University of Athens), Μaria Anastasiou(National and Kapodistrian University of Athens), George Fountzilas(Hellenic Cooperative Oncology Group), Konstantinos Palialexis(National and Kapodistrian University of Athens), Μαρία Γκοτζαμανίδου(National and Kapodistrian University of Athens), Stavros Gkolfinopoulos(National and Kapodistrian University of Athens), Evi Lianidou(Athens State University), Alexander Delides(National and Kapodistrian University of Athens), Aileen I. Fernandez(Yale University), Efthymios Kyrodimos(National and Kapodistrian University of Athens), Nikolaos G. Papadimitriou(National and Kapodistrian University of Athens), Vesal Yaghoobi(Yale University), George Papaxoinis(St Savas Hospital), Ioannis Kotsantis(National and Kapodistrian University of Athens), Αreti Strati(National and Kapodistrian University of Athens), Eleni Gagari(Andreas Sygros Hospital), Saba Shafi(Ministry of Education of the People's Republic of China), Vasiliki Xirou(Yale University), Christos Perisanidis(National and Kapodistrian University of Athens), Vassilis Kouloulias(National and Kapodistrian University of Athens), Panagiota Economopoulou(National and Kapodistrian University of Athens)
Cited by 19
Related Papers
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
|Nature|2005|1.5k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
|JAMA Oncology|2015|834
Programmed death ligand-1 expression in non-small cell lung cancer
|Laboratory Investigation|2013|753